Physician profile
Angela Long
NPI 1477083913
$2,636.71
in general payments reported to CMS, 2019-2025
22 companies · $572 in 2025
The $572 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $550 · 2023: $635 · 2024: $663 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.36 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $413.62 | 2021-2024 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.38 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $181.35 | 2021-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $180.37 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $173.74 | 2022-2024 | Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $108.97 | 2021-2024 | Linzess |
| Qol Medical, LLC | $107.55 | 2023-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $88.11 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $67.74 | 2023-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $55.96 | 2023-2024 | Dupixent |
| Madrigal Pharmaceuticals | $48.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $45.21 | 2023 | Epclusa |
| Ipsen Biopharmaceuticals, INC | $43.18 | 2025 | Iqirvo |
| Celgene Corporation | $31.74 | 2023 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $25.72 | 2024 | Axonics |
| Organon LLC | $18.59 | 2025 | Hadlima, Renflexis |
| Pfizer INC. | $18.01 | 2025 | |
| Lilly USA, LLC | $17.56 | 2024 | Omvoh |
| Amgen INC. | $17.08 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.02 | 2025 | Uzedy |
| Nestle Healthcare Nutrition INC. | $15.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.